恒瑞医药(600276.SH)取得药物临床试验批准通知

Core Viewpoint - Heng Rui Medicine (600276.SH) and its subsidiaries have received approval from the National Medical Products Administration for clinical trials of multiple drugs, indicating a significant advancement in their oncology pipeline [1] Group 1: Company Developments - The company, along with its subsidiaries Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Shengdi Medicine Co., Ltd., has been granted clinical trial approval for HRS-4508, SHR-A1811, Adalimumab injection, and Bevacizumab injection [1] - The clinical trials will focus on HRS-4508 in combination with other anti-tumor treatments for solid tumors with abnormal HER2 pathways, specifically an open-label, multicenter Phase I/II study [1]